IL6 and metastatic prostate carcinoma: Circulating levels of two proinflammatory cytokines, interleukin 6 (IL-6) and 8 (IL-8), have been found to be higher in hormone refractory and sensitive metastatic prostate cancer patients with poor prognosis, respectively [82,83].